)
Drug firm Cadila Healthcare has decided to exit from its business in Japan following a strategic review of its business.
"The company has recently completed portfolio and strategy review of its business and has decided to exit from its business in Japan, which is through 100% subsidiary company," Cadila Healthcare Ltd said in a filing to the BSE.
The Ahmedabad-based firm has operations spread across the US, Europe, Japan, Brazil, South Africa and 25 other emerging markets.
Shares of Cadila Healthcare today closed at Rs 819 apiece on the BSE, down 2.24% from its previous close.
